Cancer vaccine maker Aduro files for $86M IPO

Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week. Central to its pitch: Phase IIa data for CRS-207 combined with once-failed cancer vaccine GVAX. That study was stopped early on promising data, winning the FDA over to grab a breakthrough therapy designation. More

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.